Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Ukraine is interrogating two North Korean soldiers captured while they were fighting for Russia in the Kursk region, according to President Volodymyr Zelenskyy.

As firefighters continued to battle massive wildfires Friday, Los Angeles Fire Chief Kristin Crowley stunned many observers with an extraordinary television interview.

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, ...

Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while ...